Literature DB >> 24049067

A new link between diabetes and cancer: enhanced WNT/β-catenin signaling by high glucose.

Custodia García-Jiménez1, Jose Manuel García-Martínez, Ana Chocarro-Calvo, Antonio De la Vieja.   

Abstract

Extensive epidemiological studies suggest that the diabetic population is at higher risk of site-specific cancers. The diabetes-cancer link has been hypothesized to rely on various hormonal (insulin, IGF1, adipokines), immunological (inflammation), or metabolic (hyperglycemia) characteristics of the disease and even on certain treatments. Inflammation may have an important but incompletely understood role. As a growth factor, insulin directly, or indirectly through IGF1, has been considered the major link between diabetes and cancer, while high glucose has been considered as a subordinate cause. Here we discuss the evidence that supports a role for insulin/IGF1 in general in cancer, and the mechanism by which hyperglycemia may enhance the appearance, growth and survival of diabetes-associated cancers. High glucose triggers several direct and indirect mechanisms that cooperate to promote cancer cell proliferation, migration, invasion and immunological escape. In particular, high glucose enhancement of WNT/β-catenin signaling in cancer cells promotes proliferation, survival and senescence bypass, and represents a previously unrecognized direct mechanism linking diabetes-associated hyperglycemia to cancer. Increased glucose uptake is a hallmark of tumor cells and may ensure enhanced WNT signaling for continuous proliferation. Mechanistically, high glucose unbalances acetylation through increased p300 acetyl transferase and decreased sirtuin 1 deacetylase activity, leading to β-catenin acetylation at lysine K354, a requirement for nuclear accumulation and transcriptional activation of WNT-target genes. The impact of high glucose on β-catenin illustrates the remodeling of cancer-associated signaling pathways by metabolites. Metabolic remodeling of cancer-associated signaling will receive much research attention in the coming years. Future epidemiological studies may be guided and complemented by the identification of these metabolic interplays. Together, these studies should lead to the development of new preventive strategies for diabetes-associated cancers.

Entities:  

Keywords:  WNT; cancer; diabetes; glucose-dependent insulinotropic peptide; incretin; insulin; signaling; transcription; β-catenin

Mesh:

Substances:

Year:  2013        PMID: 24049067     DOI: 10.1530/JME-13-0152

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  54 in total

1.  mTORC2 in the center of cancer metabolic reprogramming.

Authors:  Kenta Masui; Webster K Cavenee; Paul S Mischel
Journal:  Trends Endocrinol Metab       Date:  2014-05-21       Impact factor: 12.015

2.  Impact of body mass on recurrence and progression in Chinese patients with Ta, T1 urothelial bladder cancer.

Authors:  Tianyuan Xu; Zhaowei Zhu; Xianjin Wang; Leilei Xia; Xiaohua Zhang; Shan Zhong; Fukang Sun; Yu Zhu; Zhoujun Shen
Journal:  Int Urol Nephrol       Date:  2015-05-26       Impact factor: 2.370

3.  Local Application of Isogenic Adipose-Derived Stem Cells Restores Bone Healing Capacity in a Type 2 Diabetes Model.

Authors:  Christoph Wallner; Stephanie Abraham; Johannes Maximilian Wagner; Kamran Harati; Britta Ismer; Lukas Kessler; Hannah Zöllner; Marcus Lehnhardt; Björn Behr
Journal:  Stem Cells Transl Med       Date:  2016-04-21       Impact factor: 6.940

Review 4.  Targeted Therapies: Immunologic Effects and Potential Applications Outside of Cancer.

Authors:  Anna E Kersh; Spencer Ng; Yun Min Chang; Maiko Sasaki; Susan N Thomas; Haydn T Kissick; Gregory B Lesinski; Ragini R Kudchadkar; Edmund K Waller; Brian P Pollack
Journal:  J Clin Pharmacol       Date:  2017-11-14       Impact factor: 3.126

Review 5.  Cardiovascular disease and cancer: Evidence for shared disease pathways and pharmacologic prevention.

Authors:  Farzad Masoudkabir; Nizal Sarrafzadegan; Carolyn Gotay; Andrew Ignaszewski; Andrew D Krahn; Margot K Davis; Christopher Franco; Arya Mani
Journal:  Atherosclerosis       Date:  2017-06-02       Impact factor: 5.162

6.  NF-κB and STAT3 co-operation enhances high glucose induced aggressiveness of cholangiocarcinoma cells.

Authors:  Charupong Saengboonmee; Chatchai Phoomak; Suangson Supabphol; Kyle R Covington; Oliver Hampton; Chaisiri Wongkham; Richard A Gibbs; Kazuo Umezawa; Wunchana Seubwai; Marie-Claude Gingras; Sopit Wongkham
Journal:  Life Sci       Date:  2020-10-07       Impact factor: 5.037

Review 7.  The spectrum of T cell metabolism in health and disease.

Authors:  Glenn R Bantug; Lorenzo Galluzzi; Guido Kroemer; Christoph Hess
Journal:  Nat Rev Immunol       Date:  2017-09-25       Impact factor: 53.106

Review 8.  Hyperglycemia and aberrant O-GlcNAcylation: contributions to tumor progression.

Authors:  Andréia Vasconcelos-Dos-Santos; Rafaela Muniz de Queiroz; Bruno da Costa Rodrigues; Adriane R Todeschini; Wagner B Dias
Journal:  J Bioenerg Biomembr       Date:  2018-01-11       Impact factor: 2.945

9.  Obesity and Breast Cancer: Molecular Interconnections and Potential Clinical Applications.

Authors:  Valeria Simone; Morena D'Avenia; Antonella Argentiero; Claudia Felici; Francesca Maria Rizzo; Giovanni De Pergola; Franco Silvestris
Journal:  Oncologist       Date:  2016-02-10

Review 10.  Diabetes and cancer: Associations, mechanisms, and implications for medical practice.

Authors:  Chun-Xiao Xu; Hong-Hong Zhu; Yi-Min Zhu
Journal:  World J Diabetes       Date:  2014-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.